John Harry Cross Iii.

Chief Financial Officer, Sonnet BioTherapeutics Holdings, Inc.

Companies

Senti Biosciences Holdings, Inc.Chief financial officer Mar 11, 2025 to now¹
Sonnet BioTherapeutics Holdings, Inc.Chief financial officer Apr 3, 2020 to Jul 15, 2025²

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARSenti Biosciences Holdings, Inc., Chief financial officer
2
SEC EDGARSonnet BioTherapeutics Holdings, Inc., Chief financial officer